---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-003394"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2022-01-12T23:59:59+00:00"
generated_at: "2026-06-27T18:48:02.485206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vericel estimates FY2021 revenue growth 25-26%, adj. EBITDA ~$30M, cash ~$129M

## Summary
- Preliminary FY2021 revenue growth of 25%-26% (unaudited); total adjusted EBITDA ~$30M.
- Cash and investments as of Dec 31, 2021 ~$129M.
- Company presented at 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.
- Financial results are preliminary and subject to change upon audit.

## SEC filing metadata
- accession: 0001104659-22-003394
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2022-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000110465922003394/0001104659-22-003394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000110465922003394/tm222643d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-003394
- JSON: https://secwatch.observer/filing/0001104659-22-003394.json
- Plain text: https://secwatch.observer/filing/0001104659-22-003394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.